Shots:
Kathleen spoke about new long-term SPINRAZA (nusinersen) data presented at the 3rd International Scientific Congress
She then explained the new findings from individuals with infantile-onset SMA who were treated with SPINRAZA in the pivotal ENDEAR study followed by the long-term extension SHINE study for up to 7 years
The interview also discusses Biogen’s advances…
